GlassScriptPhysician profile
Arun Kalra
NPI 1356489181
$3,250.83
in general payments reported to CMS, 2019-2025
32 companies · $330 in 2025
The $330 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,458 · 2020: $625 · 2021: $99.18 · 2022: $345 · 2024: $392 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $591 · Education: $132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $590.62 |
| Education | $131.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,177.95 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $254.79 | 2022-2025 | Opdivo |
| Genentech USA, INC. | $242.59 | 2019-2025 | Polivy |
| Lilly USA, LLC | $183.76 | 2019-2020 | |
| Astellas Pharma US INC | $169.99 | 2020 | |
| Pfizer INC. | $145.16 | 2019-2022 | |
| Kite Pharma, INC. | $125.00 | 2019 | |
| Incyte Corporation | $118.92 | 2024 | Jakafi, Monjuvi, Pemazyre |
| Amgen INC. | $117.76 | 2019-2025 | |
| Intuitive Surgical, INC. | $92.20 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.91 | 2019 | |
| Celgene Corporation | $60.28 | 2019 | |
| Merck Sharp & Dohme LLC | $49.95 | 2024 | Keytruda |
| Novocure INC. | $48.11 | 2025 | Optune Gio, Optune Lua (Novottf-200t) |
| Glaxosmithkline, LLC. | $41.84 | 2024 | Ojjaara, Jemperli, Zejula |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $34.64 | 2024 | Trodelvy |
| Alexion Pharmaceuticals, INC. | $32.79 | 2024 | Ultomiris |
| Servier Pharmaceuticals LLC | $31.26 | 2022-2024 | |
| Pharmaessentia USA Corporation | $29.53 | 2025 | Besremi |
| Coherus Oncology, INC. | $22.70 | 2024 | |
| Daiichi Sankyo INC. | $20.36 | 2025 | Datroway |
| Z-Medica, LLC | $19.68 | 2020 | |
| Tactile Systems Technology INC | $19.00 | 2025 | Nimbl, Flexitouch Plus |
| Seagen INC. | $18.27 | 2020 | |
| Rigel Pharmaceuticals, INC. | $17.88 | 2025 | Tavalisse, Gavreto, Rezlidhia |
| Bayer Healthcare Pharmaceuticals INC. | $17.76 | 2025 | |
| Eisai INC. | $17.06 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $15.15 | 2019 | |
| Tempus Ai, INC | $14.83 | 2025 | Xt Cdx |
| Viiv Healthcare Company | $14.39 | 2020 | |
| Array Biopharma INC | $14.23 | 2025 | Braftovi, Lorbrena, Mektovi |
| Exelixis INC. | $14.09 | 2024 | Cabometyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Kalra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.